[go: up one dir, main page]

PE20080844A1 - Uso de moduladores lxr para la prevencion y tratamiento del envejecimiento de la piel - Google Patents

Uso de moduladores lxr para la prevencion y tratamiento del envejecimiento de la piel

Info

Publication number
PE20080844A1
PE20080844A1 PE2007001262A PE2007001262A PE20080844A1 PE 20080844 A1 PE20080844 A1 PE 20080844A1 PE 2007001262 A PE2007001262 A PE 2007001262A PE 2007001262 A PE2007001262 A PE 2007001262A PE 20080844 A1 PE20080844 A1 PE 20080844A1
Authority
PE
Peru
Prior art keywords
lxr
prevention
treatment
skin aging
oxisterol
Prior art date
Application number
PE2007001262A
Other languages
English (en)
Inventor
Sunil Nagpal
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20080844A1 publication Critical patent/PE20080844A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN MODULADOR LXR SELECCIONADO DE OXISTEROL, NO-OXISTEROL (NATURAL O SINTETICO), 22(R)HIDROXICOLESTEROL, N-(2,2,2-TRIFLUOROETIL)-N-{4-[2,2,2-TRIFLUORO-1-HIDROXI-1-(TRIFLUOROMETIL)ETIL]FENIL}BENCENO SULFONAMIDA, ENTRE OTROS. OPCIONALMENTE PUEDE CONTENER O NO UN LIGANDO, COMO, ACIDO ALL-TRANS RETINOICO, ACIDO 6-[3-(1-ADAMANTIL)-4-METOXIFENIL]-2-NAFTOICO, ENTRE OTROS; UN ANTIOXIDANTE; FILTRO SOLAR; RETINOIDES, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION. EL MODULADOR DE LXR, INDUCE A LA EXPRESION DE LXR , LXRß, TIMP1, ASAH1, ENTRE OTROS, POR LO QUE DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO ANTI-ENVEJECIMIENTO DE LA PIEL
PE2007001262A 2006-09-19 2007-09-19 Uso de moduladores lxr para la prevencion y tratamiento del envejecimiento de la piel PE20080844A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84568506P 2006-09-19 2006-09-19

Publications (1)

Publication Number Publication Date
PE20080844A1 true PE20080844A1 (es) 2008-08-15

Family

ID=39110878

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001262A PE20080844A1 (es) 2006-09-19 2007-09-19 Uso de moduladores lxr para la prevencion y tratamiento del envejecimiento de la piel

Country Status (5)

Country Link
US (1) US20080070883A1 (es)
AR (1) AR062911A1 (es)
PE (1) PE20080844A1 (es)
TW (1) TW200819145A (es)
WO (1) WO2008036238A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
AU2007217366A1 (en) * 2006-02-27 2007-08-30 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
WO2008011071A2 (en) * 2006-07-19 2008-01-24 The Regents Of The University Of California Interactions of hedgehog and liver x receptor signaling pathways
CA2673513A1 (en) * 2006-12-19 2008-07-10 The Regents Of University Of California Inhibition of ppar gamma expression by specific osteogenic oxysterols
US20100112030A1 (en) * 2007-03-16 2010-05-06 The Regents Of The University Of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
MX2009012474A (es) * 2007-05-18 2009-12-18 Wyeth Corp Compuestos de quinazolina.
WO2009045761A1 (en) * 2007-09-28 2009-04-09 Absolute Science, Inc. Compounds and methods for treating zinc matrix metalloprotease dependent diseases
CN101951915A (zh) * 2007-12-03 2011-01-19 加利福尼亚大学董事会 用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇
BRPI0822239A2 (pt) * 2007-12-21 2015-06-30 Wyeth Llc Composto de pirazolo[1,5-a] pirimidina
BRPI0821315A2 (pt) * 2007-12-21 2019-09-24 Wyeth Llc compostos benzimidazol
US20110112135A1 (en) * 2007-12-21 2011-05-12 Singhaus Jr Robert Ray Imidazo [1,2-A] Pyridine Compounds
US20100331333A1 (en) * 2007-12-21 2010-12-30 Wyeth Llc Imidazo [1,2-B] Pyridazine Compounds
WO2009140550A2 (en) 2008-05-14 2009-11-19 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US20110190285A1 (en) * 2008-09-19 2011-08-04 Absolute Science, Inc. Methods of treating a botulinum toxin related condition in a subject
EP2349348A4 (en) * 2008-11-03 2013-06-26 Dermachip Inc COMPOSITIONS AND METHOD FOR REDUCING SIGNS FOR SKIN AGING
WO2010054229A1 (en) * 2008-11-07 2010-05-14 Wyeth Llc Quinoxaline-based lxr modulators
JP2012509334A (ja) * 2008-11-19 2012-04-19 ワイス・エルエルシー 肝x受容体(lxr)モジュレーターとしての極性キナゾリン類
WO2011006087A1 (en) * 2009-07-10 2011-01-13 The Regents Of The University Of California Inhibition of ppar gamma expression in preadipocyte cells by oxysterols
KR101766393B1 (ko) * 2010-11-30 2017-08-10 (주)아모레퍼시픽 블레오마이신 하이드로라제를 이용한 건조 피부 개선물질 스크리닝 방법
WO2012156420A1 (en) * 2011-05-17 2012-11-22 Chanel Parfums Beaute Large, hs6st2 or st8sia1 activators for preventing and/or attenuating skin ageing and/or hydrating skin
BR112014013667A2 (pt) 2011-12-06 2017-06-13 Unilever Nv composição antienvelhecimento da pele
EP2847206A4 (en) 2012-05-07 2016-01-20 Univ California OXYSTEROL ANALOGUE OXY133 FOR INDUCTION OF OSTEOGENESIS AND HEDGEHOG SIGNALING AND ADIPOGENESIS INHIBITION
AU2014259672A1 (en) 2013-05-02 2015-12-03 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
CN105132358B (zh) * 2015-07-29 2019-12-06 苏州诺普再生医学有限公司 培养获得组织工程表皮的方法及其应用
US20190365784A1 (en) * 2015-12-30 2019-12-05 Raúl Enrique MASSONE Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators
CA3090785A1 (en) 2018-02-14 2019-08-22 John Daniel Dobak Iii Novel gene classifiers and uses thereof in non-melanoma skin cancers
EP3948290A4 (en) 2019-03-26 2023-08-09 Dermtech, Inc. NEW GENE CLASSIFIERS AND THEIR USES FOR SKIN CANCERS
MX2021012206A (es) * 2019-04-05 2021-12-10 Dermtech Inc Clasificadores de genes novedosos para su uso en el monitoreo de daño ultravioleta.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60120805A (ja) * 1983-11-30 1985-06-28 Akira Kitano 皮膚化粧料
US5492894A (en) * 1991-03-21 1996-02-20 The Procter & Gamble Company Compositions for treating wrinkles comprising a peptide
US6060515A (en) * 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US20030086923A1 (en) * 1999-12-13 2003-05-08 Sparrow Carl P. Method for the prevention and/or treatment of atherosclerosis
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
JP2005509610A (ja) * 2001-10-04 2005-04-14 ユニリーバー・ナームローゼ・ベンノートシヤープ 皮膚の表皮障壁発達の増進
AU2002351412B2 (en) * 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
EP1463726A2 (en) * 2001-12-21 2004-10-06 Pharmacia Corporation Aromatic thioether liver x-receptor modulators
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003074101A1 (en) * 2002-02-28 2003-09-12 Eli Lilly And Company Method of treating atherosclerosis and hypercholesterolemia
BR0311263A (pt) * 2002-05-24 2005-04-26 Pharmacia Corp Moduladores anilino receptores-x do fìgado
JP3694494B2 (ja) * 2002-07-02 2005-09-14 三井金属鉱業株式会社 車両スライド扉の動力装置
MXPA05002914A (es) * 2002-09-17 2005-05-27 Pharmacia Corp Moduladores de los receptores x hepaticos aromaticos.
US20050036992A1 (en) * 2002-12-23 2005-02-17 Irm Llc Novel use of liver X receptor agonists
US20040259948A1 (en) * 2003-01-10 2004-12-23 Peter Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
WO2004064769A2 (en) * 2003-01-21 2004-08-05 Hector Herrera Methods for making and using topical delivery agents
KR20060008913A (ko) * 2003-04-21 2006-01-27 타그라 바이오테크놀로지스 리미티드 아스코르브산의 안정화된 유도체
US20050009837A1 (en) * 2003-05-20 2005-01-13 City Of Hope Modulators of lipid metabolism and methods of use
AU2004298486A1 (en) * 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
AU2005271737A1 (en) * 2004-08-03 2006-02-16 Wyeth Indazoles useful in treating cardiovascular diseases
CN101087754B (zh) * 2004-12-22 2012-01-18 霍夫曼-拉罗奇有限公司 环己烷衍生物
US7700595B2 (en) * 2005-03-01 2010-04-20 Wyeth Llc Cinnoline compounds

Also Published As

Publication number Publication date
US20080070883A1 (en) 2008-03-20
WO2008036238A2 (en) 2008-03-27
TW200819145A (en) 2008-05-01
AR062911A1 (es) 2008-12-17
WO2008036238A3 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
PE20080844A1 (es) Uso de moduladores lxr para la prevencion y tratamiento del envejecimiento de la piel
ES2602986T3 (es) Nuevas composiciones cosméticas y/o farmacológicas y sus aplicaciones
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
ATE486860T1 (de) Phenothiazin-derivat zur wundheilung
CO6430467A2 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosméticas o farmacéuticas
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
CL2007001873A1 (es) Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
BR0317275A (pt) Liberação controlada de uma substância ativa em um ambiente de gordura alta
BRPI0910874B8 (pt) formulação tópica para uso no tratamento tópico de uma condição da pele que resulta da produção de espécies reativas de oxigênio e/ou para a promoção da cicatrização de ferida tópica na pele de um indivíduo e uso da referida formulação
CL2007001915A1 (es) Compuesto cristalino de 6-[4-cloro-3-(4-etoxibencil)fenil]tetrahidropiran-2,3,4,5,-tetraol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso para preparar un medicamento para tratar diabetes, dislipidemia, obesidad, entre otras.
MA29851B1 (fr) Composes et compositions contenant de la diarylamine et utilisation en tant que modulateurs de recepteurs de c-kit
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
BRPI0811956A8 (pt) Solução tópica não aquosa de diclofenaco e processo para sua preparação
AR069830A1 (es) Factor viii y factor de von willebrand recombinantes modificados y metodos de uso de los mismos
BR112014002769A2 (pt) método e kit depilatório
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
CL2008000613A1 (es) Uso del acido (s,s)-(1-aminometil-3,4-dimetil-ciclopentil)-acetico para preparar un medicamento util para tratar tinnitis en un mamifero.
ES2564172T3 (es) Utilización de una composición cosmética para el cuidado de las pieles grasas
RU2009101326A (ru) Препарат для наружного применения на кожу, содержащий тритерпеновую кислоту
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
MX2007010881A (es) Composiciones de peroxido de benzoilo y metodos de uso.
ECSP056071A (es) Nueva difenilazetidinona con características fisiológicas mejoradas, correspondiente método de producción, medicamentos que contienen dicho compuesto y su uso
BR112013028920A2 (pt) álcoois terpênicos para uso em composições fragrantes e produtos perfumados

Legal Events

Date Code Title Description
FD Application declared void or lapsed